We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01411670
First Posted: August 8, 2011
Last Update Posted: December 2, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Andrea Morelli, University of Roma La Sapienza
  Purpose
The purpose of this study is to investigate the effects on systemic hemodynamics, microcirculation and organ function of human Protein C concentrate in patients with sepsis and septic shock.

Condition Intervention Phase
Sepsis Septic Shock Drug: Human protein C concentrate Drug: Activated protein C Drug: Placebo comparator Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock: Effects on Microcirculation and Organ Function.

Resource links provided by NLM:


Further study details as provided by Andrea Morelli, University of Roma La Sapienza:

Primary Outcome Measures:
  • plasma protein C activity [ Time Frame: over a period of 72 hours ]

Secondary Outcome Measures:
  • sublingual microcirculatory blood flow [ Time Frame: over a period of 72 hours ]
    Systemic hemodynamics,sublingual microcirculatory blood flow, organ function, citokynes.


Enrollment: 60
Study Start Date: January 2011
Study Completion Date: April 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Human protein C concentrate Drug: Human protein C concentrate
Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
Active Comparator: activated protein C
Continuous infusion of Activated Protein C
Drug: Activated protein C
Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
Placebo Comparator: Placebo
Standard treatment
Drug: Placebo comparator
Standard treatment

Detailed Description:
Sixty septic patients with plasma protein C activity < 60 % will be enrolled in the study. Patients will be randomly allocated to be treated with either a) a continuous infusion of human Protein C concentrate at 3 UI/Kg/hr for 72 hours to reach plasma protein C activity between 70 and 120 % b)to a continuous infusion of activated protein C at 24 micrograms/Kg/hr for 96 hours, c) a standard teatment(control; each n = 20). In all groups, norepinephrine will be titrated to achieve a mean arterial pressure (MAP) between 65 and 75 mmHg. Data from right heart catheterization, from microcirculation (SDF imaging) and from organ function as well as norepinephrine requirements will be obtained at baseline and after 24, 48, 72 hours.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Severe sepsis or septic shock with plasma activity of protein C < 60 %

Exclusion Criteria:

  • Pregnancy
  • Risk of Bleeding
  • Hemorragia
  • age < 18
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01411670


Locations
Italy
Departement of Anesthesiology and Intensive Care of the University of Rome La Sapienza
Rome, Italy, 00161
Sponsors and Collaborators
University of Roma La Sapienza
Investigators
Principal Investigator: Andrea Morelli, MD University of Roma La Sapienza
  More Information

Responsible Party: Andrea Morelli, associate professor, University of Roma La Sapienza
ClinicalTrials.gov Identifier: NCT01411670     History of Changes
Other Study ID Numbers: 2112
First Submitted: August 5, 2011
First Posted: August 8, 2011
Last Update Posted: December 2, 2015
Last Verified: December 2015

Keywords provided by Andrea Morelli, University of Roma La Sapienza:
Human Protein C
Activated protein C
Microcirculation
Septic Shock
Sepsis

Additional relevant MeSH terms:
Sepsis
Toxemia
Shock
Shock, Septic
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Protein C
Drotrecogin alfa activated
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents